« Return to News | Drug Sponsors

Merck signs HCV agreement with Roche

Wednesday, May 18, 2011 12:05 PM

Merck and Roche have signed a pact to sell Merck’s recently approved hepatitis C drug Victrelis and explore combination treatments for the disease.

Roche will promote Victrelis (boceprevir), a first-in-class protease inhibitor, in the U.S. as part of a triple combination therapy regimen that includes Roche’s injectables Pegasys (peginterferon alfa) and ribavirin. The two companies are working together to educate physicians and patients about HCV.

Additionally, Merck and Roche will collaborate to examine combinations of marketed and investigational medicines from both firms "to expedite the availability of potential new treatment regimens for patients with HCV."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.